TALEN-based gene correction
US9393257B2 · kind B2 · utility
33Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2014 |
| Grant date | Jul 19, 2016 |
| Priority date | — |
| Expiry date | May 22, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/86
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.